JiHua Group announced that its subsidiary Jiangsu Kangbeide Pharmaceutical Co., Ltd. has simultaneously received two drug registration certificates for Lisdexamfetamine transdermal patches approved and issued by the National Medical Products Administration. The drug name is Lisdexamfetamine transdermal patch, with the main ingredient being lisdexamfetamine, dosage form as a patch, specifications of 4.6mg/24 hours and 9.5mg/24 hours, registered as a Class 4 chemical drug, certificate numbers 2025S01723 and 2025S01724, drug approval numbers GuoYaoZhunZi H20254469 and GuoYaoZhunZi H20254470, valid until June 9, 2030. Kangbeide has invested approximately 20 million RMB in research and development expenses for the Lisdexamfetamine transdermal patch project